Company / Operating Income
UroGen Pharma Ltd. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$124.9M
FY2025
5-year range
-$124.9M / -$65.5M
FY2021-FY2025
Trend
-90.5%
vs FY2024
Sector context
#104 of 204
Health Care
What the data says
At -$125M, UroGen Pharma Ltd.'s operating income ranks #104 of 204 in the Health Care sector. Operating Income has fluctuated over the past 10 years, ranging from -$125M in FY2025 to $798,000 in FY2016.
Based on SEC 10-K filings.
-$125M in FY2025.
Declined from -$79M to -$125M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#104 of 204 in Health CareTop 51% of 204This company -$124.9M Sector average $107.7M
▼
-215.9% below sector average
Key checks
Key Insights
- In FY2025, operating income decreased 90.5% year-over-year.
- Ranks #104 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$124.9M | -90.5% |
| FY2024 | -$65.5M | +17.1% |
| FY2023 | -$79.0M | +14.4% |
| FY2022 | -$92.3M | +0.0% |
| FY2021 | -$92.3M | +15.7% |
| FY2020 | -$109.5M | -448.8% |
| FY2019 | -$19.9M | +74.2% |
| FY2018 | -$77.2M | -286.9% |
| FY2017 | -$19.9M | -2600.0% |
| FY2016 | $798.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026